4170 related articles for article (PubMed ID: 6597451)
21. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages.
Alleva DG; Walker TM; Elgert KD
J Leukoc Biol; 1995 Jun; 57(6):919-28. PubMed ID: 7790775
[TBL] [Abstract][Full Text] [Related]
22. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
Fogler WE; Fidler IJ
Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
[TBL] [Abstract][Full Text] [Related]
23. Tumor modulation of autoreactivity: decreased macrophage and autoreactive T cell interactions.
Yurochko AD; Burger CJ; Elgert KD
Cell Immunol; 1990 Apr; 127(1):105-19. PubMed ID: 2138515
[TBL] [Abstract][Full Text] [Related]
24. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
25. Tumoricidal activity of alveolar and peritoneal macrophages of C57BL/6 mice bearing metastatic or nonmetastatic variants of Lewis lung carcinoma.
Duffie GP; Young MR
J Leukoc Biol; 1991 Jan; 49(1):8-14. PubMed ID: 1984486
[TBL] [Abstract][Full Text] [Related]
26. Macrophage-mediated suppression of immune responses in Toxoplasma-infected mice. I. Inhibition of proliferation of lymphocytes in primary antibody responses.
Suzuki Y; Kobayashi A
Cell Immunol; 1984 May; 85(2):417-27. PubMed ID: 6325025
[TBL] [Abstract][Full Text] [Related]
27. Adherent cells (macrophages?) in tumor-bearing mice suppress MLC responses.
Garrigues HJ; Romero P; Hellström I; Hellström KE
Cell Immunol; 1981 May; 60(1):109-18. PubMed ID: 6453654
[No Abstract] [Full Text] [Related]
28. Pyran (MVE-5) reverses the inhibition of macrophage receptors for cytophilic antibody induced by soluble immune complexes.
Rao VS; Mitchell MS
J Biol Response Mod; 1983; 2(1):67-80. PubMed ID: 6606020
[TBL] [Abstract][Full Text] [Related]
29. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in connection with its high level in tumor-bearing mice.
Shibata Y; Tamura K; Ishida N
Cancer Res; 1983 Jun; 43(6):2889-96. PubMed ID: 6221795
[TBL] [Abstract][Full Text] [Related]
30. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.
Lala PK; Parhar RS; Singh P
Cell Immunol; 1986 Apr; 99(1):108-18. PubMed ID: 2944621
[TBL] [Abstract][Full Text] [Related]
31. Subversive activity of syngeneic tumor cells as an escape mechanism from immune surveillance and the role of prostaglandins.
Plescia OJ; Grinwich K; Plescia AM
Ann N Y Acad Sci; 1976; 276():455-65. PubMed ID: 1071971
[TBL] [Abstract][Full Text] [Related]
32. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.
Mullins DW; Walker TM; Burger CJ; Elgert KD
Cancer Immunol Immunother; 1997 Oct; 45(1):20-8. PubMed ID: 9353423
[TBL] [Abstract][Full Text] [Related]
33. Cellular basis for the immune response to methylcholanthrene-induced tumors in mice. Heterogeneity of effector cells.
Kearney R; Basten A; Nelson DS
Int J Cancer; 1975 Mar; 15(3):438-50. PubMed ID: 1079792
[TBL] [Abstract][Full Text] [Related]
34. Induction of macrophagic prostaglandin E2 synthesis by glioma cells.
Nakano Y; Kuroda E; Kito T; Yokota A; Yamashita U
J Neurosurg; 2006 Apr; 104(4):574-82. PubMed ID: 16619662
[TBL] [Abstract][Full Text] [Related]
35. Tumor growth changes the contribution of granulocyte-macrophage colony-stimulating factor during macrophage-mediated suppression of allorecognition.
Walker TM; Yurochko AD; Burger CJ; Elgert KD
Immunobiology; 1992 Sep; 185(5):427-39. PubMed ID: 1452214
[TBL] [Abstract][Full Text] [Related]
36. Suppression of polyclonal, tumor cell and alloantigen-induced proliferation: identification of cyclooxygenase pathway dependent and independent mechanisms.
Hogan KT; Hollingsworth MA; Seymour RE; Quinn MK; Evans DL
Immunopharmacology; 1984 Feb; 7(1):49-57. PubMed ID: 6232242
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma.
Young MR; Hoover CS
J Natl Cancer Inst; 1986 Aug; 77(2):425-9. PubMed ID: 2942724
[TBL] [Abstract][Full Text] [Related]
38. Tumour growth causes suppression of autoreactive T-cell proliferation by disrupting macrophage responsiveness to interferon-gamma.
Alleva DG; Burger CJ; Elgert KD
Scand J Immunol; 1994 Jan; 39(1):31-8. PubMed ID: 7904773
[TBL] [Abstract][Full Text] [Related]
39. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation.
Treves AJ; Cohen IR; Feldman M
Isr J Med Sci; 1976; 12(4-5):369-84. PubMed ID: 1084880
[TBL] [Abstract][Full Text] [Related]
40. An immunoregulatory factor associated with spleen cells from tumor-bearing animals. I. Effect on tumor growth and antibody production.
Isakov N; Segal S; Hollander N; Feldman M
Int J Cancer; 1978 Oct; 22(4):465-70. PubMed ID: 359490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
